Mylan Rebates Doomed EpiPen Rival, Sanofi Says
EpiPen maker Mylan improperly preserved its monopoly on epinephrine auto-injectors by offering big rebates to insurers that refused to cover a competing product, Sanofi-Aventis charged in a complaint filed Monday in...To view the full article, register now.
Already a subscriber? Click here to view full article